ArticleBMC neurology2025
An integrated bioinformatics and machine learning approach to identifying biomarkers connecting parkinson's disease with purine metabolism-related genes.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundParkinson's disease (PD), a prevalent neurodegenerative disorder in the aging population, poses significant challenges in unraveling its pathogenesis and progression. A key area of investigation is the disruption of oncological metabolic networks in PD, where diseased cells display distinct metabolic profiles compared to healthy counterparts. Of particular interest are Purine Metabolism Genes (PMGs), which play a pivotal role in nucleic acid synthesis.
methodsIn this study, bioinformatics analyses were employed to identify and validate PMGs associated with PD. A set of 20 candidate PMGs underwent differential expression analysis. GSEA and GSVA were conducted to explore the biological roles and pathways of these PMGs. Lasso regression and SVM-RFE methods were applied to identify hub genes and assess the diagnostic efficacy of the nine PMGs in distinguishing PD. The correlation between these hub PMGs and clinical characteristics was also explored. Validation of the expression levels of the nine identified PMGs was performed using the GSE6613 and GSE7621 datasets.
resultsThe study identified nine PMGs related to PD: NME7, PKM, RRM2, POLR3 C, POLA1, PDE6 C, PDE9 A, PDE11 A, and AMPD1. Biological function analysis highlighted their involvement in processes like neutrophil activation and immune response. The diagnostic potential of these nine PMGs in differentiating PD was found to be substantial.
conclusionsThis investigation successfully identified nine PMGs associated with PD, providing valuable insights into potential novel biomarkers for this condition. These findings contribute to a deeper understanding of PD's pathogenesis and may aid in monitoring its progression, offering a new perspective in the study of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.